Search

CASE Direct #3: Destiny-Breast 09 Case Study



Agenda

9:00-9:20 Keynote speech

- Destiny-Breast 09 Phase III clinical research and progress

  • Dr. Sara M Tolaney, Dana Farber Cancer Center, Harvard Medical School


9:20-9:50 Expert commentary

-To elaborate on the past and present of the DESTINY-Breast series of studies, predict the results of DB09 from DB03, who will be the overlord of advanced breast cancer research?

  • From clinical data perspective: Dr. Sheng Luo, Duke University

  • From clinical mechanism perspective: Dr. Youwen He, Duke University


9:50-10:30: Panel Discussion

  • Dr. Sheng Luo, Duke University

  • Dr. Sara M Tolaney, Dana Farber Cancer Center, Harvard Medical School

  • Dr. Youwen He, Duke University

  • Dr. Lei Fan, Fudan University Cancer Hospital

  • Dr. Yizhou Jiang, Fudan University Shanghai Cancer Center

  • Dr. Hengyu Li, The Changhai Hospital of Navy Military Medical University

  • Dr. Wenfeng Li, The Affiliated Hospital of Qingdao University

  • Dr. Jia Wang,The Second Hospital of Dalian Medical University


 

Our Guest Speakers


Dr. Sara M Tolaney, Dana Farber Cancer Center, Harvard Medical School

Sara Tolaney, MD, MPH is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and is internationally recognized for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Dr. Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Masters in Public Health from Harvard School of Public Health.

Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She currently chairs several registration studies in these areas and also leads many investigator-initiated trials. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals such as the New England Journal, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology.



Dr. Sheng Luo, Duke University

Dr. Luo is professor of Biostatistics & Bioinformatics at Duke University. He received his PhD in Biostatistics from The Johns Hopkins University. He is Fellow of American Statistical Association (ASA) and Elected Member of International Statistical Institute. Dr. Luo is a leading expert in statistical methods of the design and analysis of clinical trials and observational studies. He has more than 100 peer-reviewed articles published in high-impact clinical and statistical journals. Dr. Luo has served as PI of multiple NIH grants on statistical methodology development. He is also PI of multiple projects regarding novel latent variable modeling and various neurodegenerative disorders rating scale development, validation, and translation funded by Parkinson’s Foundation, CHDI Foundation, and Movement Disorders Society.


Dr. Youwen He, Duke University

Dr. You-Wen He received his M.D. from the Fourth Military Medical University in 1986 in China and his Ph.D. in Immunology from the University of Miami School of Medicine in 1996. He completed his postdoctoral training in Dr. Michael J. Bevan’s laboratory at HHMI/University of Washington and took an Assistant Professor position in the Department of Immunology at Duke University Medical Center in year 2000. Dr. He is currently a Professor of Immunology at Duke University Medical Center. His lab has been studying T cell biology in health and diseases. The current effort in his lab is focused on developing new strategies to treat cancers using immunotherapies. His lab is examining how antibodies/antagonists to complement receptors and the cytokine IL-10 are used to treat different tumors in animal models and human. Dr. He is also leading three highly personalized cancer immunotherapy clinical trials treating patients with glioblastoma multiforme and advanced solid tumors. He also studies the functional role of the fundamental intracellular process termed autophagy in T lymphocyte function.



Dr. Lei Fan, Fudan University Cancer Hospital

Dr. Fan Lei graduated from the Department of oncology, Shanghai Medical College, Fudan University; She has been studying for breast cancer since 2004. She went to Harvard University medical school for further training, and she also received systematic training in breast cancer comprehensive treatment and clinical research at the MGH cancer center. She focused on diagnosis and treatment of breast benign and malignant diseases and individualized comprehensive treatment of breast cancer. Her research is mainly engaged in clinical research of breast cancer and clinical application related basic research. She was supported by Avon research programs, GCI international projects and other international projects and already published more than 20 papers included in SCI, which are included in top magazines such as Lancet tumor.


Dr. Yizhou Jiang, Fudan University Shanghai Cancer Center

Dr. Yi-Zhou Jiang, researcher of Fudan University Shanghai Cancer Center, graduated from Fudan University. His research efforts have been focused on molecular subtyping and precision treatment of breast cancer. His work has centered on the following: 1. Defining molecular profiling of triple-negative breast cancer using multiple-omic data (including genomic, transcriptomic, proteomic and metabolomic profiling). Using high-throughput technology to determine genetic alterations in breast cancer during neoadjuvant chemotherapy and metastasis. 2. Proposing precision treatment strategies of triple-negative breast cancer. Based on our subtyping system, establishing the prognostic models and identifying potential therapeutic targets for triple-negative breast cancer. 3. Identifying the molecular mechanisms by which breast cancer cells can survive chemotherapy and HER-2 targeted therapy, leading to recurrences, relapses, and metastasis. In recent five years, Dr. Yi-Zhou Jiang has published 28 articles in journals including Cancer Cell, Cell Metabol, Cell Res, Nat Commun, Science Adv, Mol Cancer, Cancer Res and Clin Cancer Res as the first or corresponding author. These findings were included in guidelines from the European Group on Tumor Marker and validated in clinical trials.



Dr. Jia Wang,The Second Hospital of Dalian Medical University

Jia Wang, MD, PhD, is the vice director of the department of Breast Surgery, 2nd hospital of Dalian Medical University.

Dr. Wang received her medical degree from China medical university. She subsequently completed her residency in Pathology at affiliated hospital of Kagoshima University Japan. She received her PhD degree from Kagoshima university, and got post-doctoral fellowships in medical oncology at Kyushu university Japan. She went back to her motherland at October 2013. From that time, serves as a breast surgeon until now.

Her research focuses on the development of evaluating the response of neoadjuvant chemotherapy of breast cancer by artificial intelligence and early predicting neoadjuvant chemotherapy drug-resistant populations. She has developed a phase II randomized clinical trial of Eribulin combined with carboplatin in the treatment of Her2-negative operable or locally advanced breast cancer after resistance to anthracycline and Taxane.


Dr. Hengyu Li, The Changhai Hospital of Navy Military Medical University

Li Hengyu is the executive director of breast and thyroid surgery of Changhai Hospital, doctor of surgery and postdoctoral in biology. His majority is diagnosis and treatment of breast and thyroid diseases, in particular, comprehensive treatment of breast tumor surgery, specializes in breast cancer plastic surgery, breast cancer chemotherapy, targeting and immunotherapy. Surgery for thyroid tumors. He published nearly 40 SCI papers, including nearly 20 SCI papers published by communication, the first and co-first authors, and authorized 6 national invention patents. He is also the Secretary General and vice chairman of the Yangtze River academic belt alliance; Young member of breast oncology group, oncology branch, Chinese Medical Association; Anti cancer association breast cancer Specialized Committee National Youth Committee and Shanghai Municipal Committee; Member of the youth Expert Committee of the Chinese society of Clinical Oncology (CSCO), reviewers of many SCI magazines. He participated in many international and domestic multi center research projects such as AFFINTY.



Dr. Wenfeng Li, The Affiliated Hospital of Qingdao University

Professor Li Wenfeng is the deputy chief physician of breast oncology department of the Affiliated Hospital of Qingdao University. She graduated from Shanghai Cancer Hospital of Fudan University with a doctor's degree in oncology. She is member of China Anti-Cancer Association breast cancer Specialized youth Committee and member, Standing Committee of Shandong Anti-Cancer Association cancer psychology Committee. She also worked as a visiting scholar in the cancer center of Houston Methodist Hospital.

Professor Li has worked in the field of oncology for 20 years and specializes in the treatment of breast cancer and lung cancer, especially in breast cancer chemotherapy, radiotherapy, endocrine therapy, targeted therapy and other comprehensive treatment. She extensively studied in terms of genetic susceptibility, recurrence and metastasis risk assessment, and multidisciplinary treatment of young/early-onset breast cancer. She has participated in a number of national, provincial and ministerial projects, won a third prize for scientific and technological progress in Shandong Province, and published more than 20 high-quality works in academic journals.


 

#cancer #breastcancer #destiny #cancertreatment #cancerresearch #cancerhealth

31 views0 comments